Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins
The CEO is focusing on growing tablet sales in the US market, addressing life science challenges. The upcoming peanut allergy trial focuses on safety, with efficacy measurements in the next phase. Pediatric launches in Europe will leverage existing channels. The house dust mite trial in China aims for approval by 2028.